Mazindol: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
Line 61: Line 61:
[[Category:Sympathomimetic amines]]
[[Category:Sympathomimetic amines]]
[[Category:Central nervous system stimulants]]
[[Category:Central nervous system stimulants]]
== Mazindol ==
<gallery>
File:Mazindol.svg|Mazindol
File:Mazindol3Dan.gif|Mazindol
File:Chemrat Mazindol.svg|Mazindol
File:Mazindol Tautomer Pharmacophore.svg|Mazindol
File:Mazindols 384a-p.svg|Mazindol
File:Mazindols 388a-g.svg|Mazindol
File:Mazindols 389a-c.svg|Mazindol
File:Mazindol analogs 2.svg|Mazindol
File:Mazindol tautomers.svg|Mazindol
File:Mazindol synthesis.svg|Mazindol
File:Mazindol synthesis (alternative).svg|Mazindol
</gallery>

Revision as of 01:28, 20 February 2025

Article about the use of Mazindol in medical treatment


Mazindol
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Mazindol is a sympathomimetic amine used primarily as an anorectic agent in the treatment of obesity. It functions as a central nervous system stimulant and is chemically related to amphetamine.

Pharmacology

Mazindol acts as a monoamine reuptake inhibitor, primarily affecting the reuptake of norepinephrine and dopamine. This action increases the levels of these neurotransmitters in the synaptic cleft, leading to increased stimulation of the central nervous system.

Medical Uses

Mazindol is prescribed for short-term management of exogenous obesity. It is typically used in conjunction with a reduced-calorie diet and exercise. The drug is intended for patients with a body mass index (BMI) of 30 or greater, or 27 or greater in the presence of other risk factors such as hypertension, diabetes mellitus, or dyslipidemia.

Side Effects

Common side effects of mazindol include:

Serious side effects may include:

Contraindications

Mazindol is contraindicated in patients with:

History

Mazindol was first introduced in the 1970s and was marketed under various brand names, including Sanorex and Mazanor. Its use has declined due to the availability of newer weight-loss medications and concerns about its side effects.

Regulation

Mazindol is classified as a Schedule IV controlled substance in the United States, indicating it has a low potential for abuse relative to substances in Schedule III.

Research

Recent studies have explored the potential use of mazindol in treating narcolepsy and attention deficit hyperactivity disorder (ADHD), due to its stimulant properties.

Also see

References

<references group="" responsive="1"></references>


External links

Mazindol